Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post hoc analysis of the CANVAS and CREDENCE trials - PubMed
6 hours ago
- #Urinary tract infection
- #SGLT2 inhibitors
- #Type 2 diabetes
- The study analyzed the risk of urinary tract infections (UTIs) with SGLT2 inhibitors, specifically canagliflozin, in patients with type 2 diabetes.
- Urinary dipstick findings, such as leukocyte esterase (LE) and nitrite, were examined for their association with UTI risk.
- Abnormal LE and nitrite results were linked to higher UTI risk, but canagliflozin did not significantly increase this risk.
- The study included 8,614 participants from the CANVAS and CREDENCE trials.
- Findings suggest that SGLT2 inhibitors like canagliflozin can be used without significantly increasing UTI risk, even in patients with abnormal dipstick results.